Cargando…
Molecular subtyping improves prognostication of Stage 2 colorectal cancer
BACKGROUND: Post-surgical staging is the mainstay of prognostic stratification for colorectal cancer (CRC). Here, we compare TNM staging to consensus molecular subtyping (CMS) and assess the value of subtyping in addition to stratification by TNM. METHODS: Three hundred and eight treatment-naïve col...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882162/ https://www.ncbi.nlm.nih.gov/pubmed/31775679 http://dx.doi.org/10.1186/s12885-019-6327-4 |
_version_ | 1783474094984921088 |
---|---|
author | Purcell, Rachel V. Schmeier, Sebastian Lau, Yee Chen Pearson, John F. Frizelle, Francis A. |
author_facet | Purcell, Rachel V. Schmeier, Sebastian Lau, Yee Chen Pearson, John F. Frizelle, Francis A. |
author_sort | Purcell, Rachel V. |
collection | PubMed |
description | BACKGROUND: Post-surgical staging is the mainstay of prognostic stratification for colorectal cancer (CRC). Here, we compare TNM staging to consensus molecular subtyping (CMS) and assess the value of subtyping in addition to stratification by TNM. METHODS: Three hundred and eight treatment-naïve colorectal tumours were accessed from our institutional tissue bank. CMS typing was carried out using tumour gene-expression data. Post-surgical TNM-staging and CMS were analysed with respect to clinicopathologic variables and patient outcome. RESULTS: CMS alone was not associated with survival, while TNM stage significantly explained mortality. Addition of CMS to TNM-stratified tumours showed a prognostic effect in stage 2 tumours; CMS3 tumours had a significantly lower overall survival (P = 0.006). Stage 2 patients with a good prognosis showed immune activation and up-regulation of tumour suppressor genes. CONCLUSIONS: Although stratification using CMS does not outperform TNM staging as a prognostic indicator, gene-expression based subtyping shows promise for improved prognostication in stage 2 CRC. |
format | Online Article Text |
id | pubmed-6882162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68821622019-12-03 Molecular subtyping improves prognostication of Stage 2 colorectal cancer Purcell, Rachel V. Schmeier, Sebastian Lau, Yee Chen Pearson, John F. Frizelle, Francis A. BMC Cancer Research Article BACKGROUND: Post-surgical staging is the mainstay of prognostic stratification for colorectal cancer (CRC). Here, we compare TNM staging to consensus molecular subtyping (CMS) and assess the value of subtyping in addition to stratification by TNM. METHODS: Three hundred and eight treatment-naïve colorectal tumours were accessed from our institutional tissue bank. CMS typing was carried out using tumour gene-expression data. Post-surgical TNM-staging and CMS were analysed with respect to clinicopathologic variables and patient outcome. RESULTS: CMS alone was not associated with survival, while TNM stage significantly explained mortality. Addition of CMS to TNM-stratified tumours showed a prognostic effect in stage 2 tumours; CMS3 tumours had a significantly lower overall survival (P = 0.006). Stage 2 patients with a good prognosis showed immune activation and up-regulation of tumour suppressor genes. CONCLUSIONS: Although stratification using CMS does not outperform TNM staging as a prognostic indicator, gene-expression based subtyping shows promise for improved prognostication in stage 2 CRC. BioMed Central 2019-11-27 /pmc/articles/PMC6882162/ /pubmed/31775679 http://dx.doi.org/10.1186/s12885-019-6327-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Purcell, Rachel V. Schmeier, Sebastian Lau, Yee Chen Pearson, John F. Frizelle, Francis A. Molecular subtyping improves prognostication of Stage 2 colorectal cancer |
title | Molecular subtyping improves prognostication of Stage 2 colorectal cancer |
title_full | Molecular subtyping improves prognostication of Stage 2 colorectal cancer |
title_fullStr | Molecular subtyping improves prognostication of Stage 2 colorectal cancer |
title_full_unstemmed | Molecular subtyping improves prognostication of Stage 2 colorectal cancer |
title_short | Molecular subtyping improves prognostication of Stage 2 colorectal cancer |
title_sort | molecular subtyping improves prognostication of stage 2 colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882162/ https://www.ncbi.nlm.nih.gov/pubmed/31775679 http://dx.doi.org/10.1186/s12885-019-6327-4 |
work_keys_str_mv | AT purcellrachelv molecularsubtypingimprovesprognosticationofstage2colorectalcancer AT schmeiersebastian molecularsubtypingimprovesprognosticationofstage2colorectalcancer AT lauyeechen molecularsubtypingimprovesprognosticationofstage2colorectalcancer AT pearsonjohnf molecularsubtypingimprovesprognosticationofstage2colorectalcancer AT frizellefrancisa molecularsubtypingimprovesprognosticationofstage2colorectalcancer |